Compare OPAL & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | TENX |
|---|---|---|
| Founded | 1998 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 71.1M |
| IPO Year | 2021 | 2001 |
| Metric | OPAL | TENX |
|---|---|---|
| Price | $2.03 | $1.83 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $2.72 | ★ $29.67 |
| AVG Volume (30 Days) | 174.4K | ★ 9.8M |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,975,000.00 | N/A |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.34 | N/A |
| 52 Week Low | $1.65 | $1.31 |
| 52 Week High | $2.87 | $19.40 |
| Indicator | OPAL | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 23.99 |
| Support Level | $2.04 | $1.31 |
| Resistance Level | $2.35 | $2.43 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.02 | 0.38 |
| Stochastic Oscillator | 51.25 | 37.50 |
OPAL Fuels Inc is a fully integrated leader in the capture and conversion of biogas into low-carbon-intensity renewable natural gas and Renewable Power. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-decarbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas. The Company has three operating segments: RNG Fuel, Fuel Station Services, and Renewable Power.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.